Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Erratum Free access | 10.1172/JCI19190E1

Osteopontin: a bridge between bone and the immune system

Ellen M. Gravallese

Find articles by Gravallese, E. in: JCI | PubMed | Google Scholar

Published August 15, 2003 - More info

Published in Volume 112, Issue 4 on August 15, 2003
J Clin Invest. 2003;112(4):627–627. https://doi.org/10.1172/JCI19190E1.
© 2003 The American Society for Clinical Investigation
Published August 15, 2003 - Version history
View PDF

Related article:

Osteopontin: a bridge between bone and the immune system
Ellen M. Gravallese
Ellen M. Gravallese
Commentary

Osteopontin: a bridge between bone and the immune system

  • Text
  • PDF
Abstract

The molecular mechanisms underlying the putative role of osteopontin in the chronic inflammatory disease rheumatoid arthritis are unclear. A study in a murine model of arthritis now demonstrates that a specific antibody directed against the exposed osteopontin epitope SLAYGLR is capable of preventing inflammatory cell infiltration in arthritic joints.

Authors

Ellen M. Gravallese

×

Original citation: J. Clin. Invest.112:147–149 (2003). doi:10.1172/JCI19190.

Citation for this erratum: J. Clin. Invest.112:627 (2003). doi:10.1172/JCI19190E1.

During the preparation of this manuscript for publication, errors were introduced into the text. The corrected paragraph appears below. We regret these errors.

Arthritis in the setting of OPN deficiency

Based on this information, one might expect that arthritis would be significantly attenuated in mice deficient in OPN. In fact this has been demonstrated in a CAIA model of RA (13) similar to that used in the study presented in this issue of the JCI (4). OPN-deficient mice were found to have marked attenuation of joint swelling and articular cartilage destruction compared with arthritic wild-type mice and had no increase in urinary levels of deoxypyridinoline, a marker of bone destruction (13). These data support a role for OPN in both the inflammatory and the joint-destructive processes in arthritis. Interestingly, however, these results were called into question in a recent report in Science (14) in which OPN was deleted by homologous recombination of strain 129-derived cells, and backcrossed into a CIA- and CAIA-susceptible strain for 12 generations. These authors then induced CIA and CAIA in the OPN-deficient mice and in littermates and demonstrated no effect of OPN deficiency in either form of murine arthritis. They concluded that prior observations in OPN-deficient mice showing protection from arthritis may have resulted from the influence of polymorphic genes linked to OPN from strain 129, rather than from the deletion of OPN itself. These authors provided a list of several other genes linked to the deleted region that could be important for arthritis pathogenesis.

Version history
  • Version 1 (August 15, 2003): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts